Liver enzyme elevations among patients on antiretroviral therapy (ART) were determined by prospectively evaluating aspartate aminotransferase (AST) data in a cohort of patients in Kampala over 36 months. A proportion of patients had hepatitis B virus (HBV) status determined. Hepatotoxicity was graded I to IV according to the AIDS Clinical Trial Group criteria. Of 546 patients, 377 (69%) were women; overall median baseline CD4+ T-cell was 97/μL (interquartile range [IQR] 20–164). Hepatitis B surface antigen (HBsAg) was detected in 42 (9%) of 470 persons. ART included lamivudine, with either nevirapine and d4T (74%) or efavirenz and AZT (26%). Median (IQR) AST level at baseline was 35 (27, 53 IU/L). Over 36 months, only eight patients had grade III AST elevation. Neither HBsAg nor ART regimen influenced AST levels. Male gender and CD4+ change from baseline were correlated with AST elevation. Patients with HIV/HBV co-infection were not at an increased risk of AST elevation, which occurred uncommonly in this setting.
SulkowskiMS, ThomasDL, ChaissonRE, MooreRD. Elevated liver enzymes following initiation of antiretroviral therapy. JAMA2000;19:2526–7
2.
LanaR, NunezM, MendozaJL, SorianoV. Rate and risk factors of liver toxicity in patients receiving antiretroviral therapy. Med Clin (Barc)2001;117:607–10
3.
WeberR, SabinCA, Friis-MollerN, Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med2006;166:1632–41
4.
SulkowskiMS. Management of hepatic complications in HIV-infected persons. J Infect Dis2008;197(Suppl. 3):S279–93
5.
OfotokunI, SmithsonSE, LuC, EasleyKA, LennoxJL. Liver enzymes elevation and immune reconstitution among treatment-naïve HIV-infected patients instituting antiretroviral therapy. Am J Med Sci2007;334:334–41
6.
SanneI, Mommeja-MartinH, HinkleJ, Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis2005;191:825–9
7.
MbouguaJB, LaurentC, KouanfackC, Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon. BMC Public Health2010;10:105–15
8.
ThioCL, SeabergEC, SkolaskyRJr, HIV-1, hepatitis B virus and risk of liver related mortality in the Multicenter Cohort Study (MACS). Lancet2002;360:1921–6
9.
KamyaM, Mayanja-KizzaH, KambuguA. Predictors of long-term viral failure among Ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr2007;46:187–93
10.
WeidlePJ, MooreD, MerminJ, Liver enzymes improve over twenty-four months of first line non-nucleoside reverse trancriptase inhibitor-based therapy in rural Uganda. AIDS Patient Care STDS2008;10:787–95
11.
MugyenyiP, WalkerS, HakimJ, Routine versus clinicaly driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomized non-inferiority trial. Lancet2010;375:123–31
12.
NúñezM, LanaR, MendozaJL, Martín-CarboneroL, SorianoV. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr2001;27:426–31
13.
BurnettRJ, FrancoisG, KewMC, Hepatitis B virus and human immunodeficiency virus co-infection in sub-Saharan Africa: a call for further investigation. Liver Int2005;25:201–13
14.
OcamaP, KatwereM, PiloyaT, The spectrum of liver diseases in HIV infected individuals at an HIV treatment clinic in Kampala, Uganda. Afr Health Sci2008;8:8–12
15.
IwalokunBA, HodonuSO, OlaleyeBM, OlabisiOA. Seroprevalence and biochemical features of hepatitis B surface antigenemia in patients with HIV-1 infection in Lagos, Nigeria. Afr J Med Sci2006;35:337–43
16.
HoffmannCJ, CharalambousS, ThioCL, Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS2007;21:1301–8
17.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of Chronic Hepatitis B. J Hepatol2009;50:227–43
18.
ThioC, LocarniniS. Treatment of HIV-HBV co-infection: clinical and virological issues. AIDS Rev2007;9:40–53
19.
BelliniC, KeiserO, ChaveJP, Liver enzyme elevation after lamivudine withdrawal in HIV-hepatitis B virus co-infected patients: the Swiss HIV Cohort Study. HIV Med2009;10:12–18
20.
BhattacharyaD, KatzensteinD, WongA, Alanine aminotransferase levels are not significantly elevated in patients with HIV/HBV co-infection and lamivudine resistance. Int J STD AIDS2008;19:780–1
21.
LivingstonSE, SimonettiJP, BulkowLR, Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F. Gastroenterology2007;133:1452–7
22.
TedaldiE, PetersL, NeuhausJ, Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. Clin Infect Dis2008;47:1468–75
23.
SerembaE, OcamaP, OpioKC, validity of Rapid Strip Assay test for detecting HBsAg in patients admitted to hospital in Uganda. J Med Virol2010;82:1334–40
24.
CastelnuovoB, YukaM, KiraggaA, MosesK, PhilippaE, KambuguA. Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first three years after antiretroviral therapy in an urban African cohort. Clin Infect Dis2009;49:965–72
25.
MehtaSH, ThomasDL, TorbensonM, The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection. Hepatology2005;41:123–31
26.
SulkowskiMS, MehtaSH, TorbensonMS, Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS2007;16:2209–16
27.
SellierP, SchnepfN, JarrinI, Description of liver disease in a cohort of HIV/HBV coinfected patients. J Clin Virol2010;47:13–17
